EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer

Mohamed Fathi Saleh, Akihiro Nita, Yudai Ohta, Aya Kobayashi, Hao Li, Yasuhisa Sakamoto, Toshiro Moroishi iD

Cancer Science · 2026

DOI: 10.1111/cas.70299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Mohamed Fathi Saleh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ferroptosis, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Center Initiative for High Depth Omics, Kato Memorial Bioscience Foundation, Foundation for Promotion of Cancer Research in Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hippo pathway effector Yes‐associated protein (YAP) and transcriptional co‐activator with PDZ‐binding motif (TAZ) play a critical role in promoting lung cancer progression, but paradoxically increase tumor cell sensitivity to ferroptosis, a form of lipid peroxidation‐driven cell death. The mechanism through which YAP/TAZ‐high cells evade ferroptosis during cancer progression remains unclear. Here, we showed that YAP/TAZ‐low lung cancer cells confer durable ferroptosis resistance to neighboring YAP/TAZ‐high cells through a non‐cell‐autonomous mechanism. Using murine lung carcinoma cell coculture models, we demonstrated that transient exposure to YAP/TAZ‐deficient cells induces a stable, contact‐independent ferroptosis‐resistant state in wild‐type (WT) cells, enhancing their metastatic seeding capacity in vivo. This adaptation is mediated by the upregulation of Gch1 , which encodes GTP cyclohydrolase 1 and suppresses ferroptosis via the synthesis of the antioxidant metabolite tetrahydrobiopterin (BH4). GCH1 overexpression alone was sufficient to confer ferroptosis resistance in WT cells, whereas conditioned medium from YAP/TAZ‐deficient cells replicated this effect, indicating that a soluble factor is involved in Gch1 induction. Importantly, the genetic deletion of Gch1 in YAP/TAZ‐deficient cells abolished their ability to protect WT cells, confirming its essential role in this intercellular program. Our findings revealed a Hippo pathway‐linked ferroptosis resistance mechanism and suggested that intra‐tumoral heterogeneity in YAP/TAZ activity promotes metastatic fitness by enabling the survival of ferroptosis‐prone cells via antioxidant signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisLung NeoplasmsProtein Serine-Threonine KinasesAnimalsHippo Signaling PathwayMiceHumansCell Line, TumorSignal TransductionYAP-Signaling ProteinsTranscription FactorsAdaptor Proteins, Signal TransducingTranscriptional Coactivator with PDZ-Binding Motif ProteinsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

GCH1ferroptosis resistancehippo pathwayintercellular communicationlung cancer

Substanzen

Protein Serine-Threonine KinasesYAP-Signaling ProteinsTranscription FactorsAdaptor Proteins, Signal TransducingTranscriptional Coactivator with PDZ-Binding Motif Proteins

Autor:innen und Institutionen

  • Division of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research Institute of Science Tokyo, Tokyo, Japan.
  • Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Toshiro Moroishi

Förderung

  • Medical Research Center Initiative for High Depth Omics
  • Kato Memorial Bioscience Foundation
  • Foundation for Promotion of Cancer Research in Japan
  • Princess Takamatsu Cancer Research Fund
  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency
  • Multilayered Stress Diseases
  • Nanken-Kyoten

Zitieren

APA

Saleh, M. F., Nita, A., Ohta, Y., Kobayashi, A., Li, H., Sakamoto, Y., & Moroishi, T. (2026). Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70299

Vancouver

Saleh MF, Nita A, Ohta Y, Kobayashi A, Li H, Sakamoto Y, et al. Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer. Cancer Science. 2026. doi:10.1111/cas.70299

BibTeX
@article{Saleh2026,
  author = {Saleh, Mohamed Fathi and Nita, Akihiro and Ohta, Yudai and Kobayashi, Aya and Li, Hao and Sakamoto, Yasuhisa and Moroishi, Toshiro},
  title = {Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70299}
}
Kostenlos starten →